This year’s Opening Session of ACR Convergence 2025 featured a well-known thought leader on physician burnout, Dr. Tait Shanafelt, who provided insight into the risk of burnout and how to prevent it. Key leadership also addressed research advocacy and more.
Updating the last iteration in 1999, the new ACR Guideline for Management of SLE was unveiled at ACR Convergence 2025, providing rheumatologists an organ-based approach for therapeutic options for specific lupus manifestations.
At this ACR Convergence session, experts provided an overview of the new ACR guideline for juvenile idiopathic arthritis.
Dr. David Pisetsky curated the research presented at ACR Convergence 2025 and answers the question “What new research on psoriatic arthritis has the potential to impact patient care or future research?”
Dr. Philip Seo highlights the latest research into the assessment and treatment of giant cell arteritis presented during ACR Convergence 2025.
At this ACR Convergence 2025 session, clinicians discussed complex and difficult-to-diagnose pediatric cases.
At this ACR Convergence 2025 session, the speaker highlighted ways complementary and alternative medicine can be used alongside traditional medical treatments.
Three experts discussed recent notable research of interest to rheumatology professionals across a range of topics.
The FDA has accepted a biologics license application for nano-encapsulated sirolimus with pegylated-adricase (NASP), a combination treatment designed to reduce serum uric acid levels in patients with uncontrolled gout.